Name: Overcoming Challenges: supporting healthcare startups in Australia
Uploaded: 2023-05-22T05:14:33.362Z
Duration: 317.1

MKFV.mp4

Untitled Descript Export.vtt

Subtitles

{{00:00:05}}
Hi, I am Kumaran Mani.

{{00:00:07}}
I'm Associate Director

{{00:00:08}}
of Business Development

{{00:00:09}}
for AstraZeneca in

{{00:00:09}}
Australia and New Zealand.

{{00:00:11}}
I also look after the Digital

{{00:00:12}}
Health Initiative, AI in

{{00:00:14}}
Australia and New Zealand, as

{{00:00:15}}
well as our health innovation

{{00:00:16}}
hub, which is part of a

{{00:00:18}}
24 hubs around the world.

{{00:00:28}}
The two main challenges for a

{{00:00:29}}
startup in Australia, number

{{00:00:30}}
one is access expertise

{{00:00:33}}
and experience and sharing

{{00:00:35}}
the knowledge,  of how to

{{00:00:36}}
get the product to market.

{{00:00:38}}
Second one is how do we

{{00:00:39}}
commercialize those technology

{{00:00:41}}
in Australia and beyond?

{{00:00:43}}
So in those two fields as

{{00:00:45}}
a AstraZeneca, what we do

{{00:00:46}}
is we are partnered with

{{00:00:48}}
Universities Resistance

{{00:00:49}}
Institutes and Australian

{{00:00:50}}
government to bring our

{{00:00:52}}
global mentoring program.

{{00:00:53}}
Through this mentoring

{{00:00:54}}
program, startup

{{00:00:55}}
companies have access

{{00:00:56}}
to over 250,  global

{{00:00:59}}
mentors from AstraZeneca,

{{00:01:00}}
from R&D, commercial

{{00:01:02}}
finance procurement.

{{00:01:03}}
So the needs, as the need

{{00:01:05}}
evolve for startup companies,

{{00:01:06}}
they can access these experts

{{00:01:09}}
within a Zeneca to guide

{{00:01:11}}
them through the process to

{{00:01:12}}
take their technology and

{{00:01:13}}
product to the next level.

{{00:01:14}}
So access to skills and

{{00:01:16}}
knowledge number one ,Number

{{00:01:18}}
two is AstraZeneca also

{{00:01:19}}
partner, collaborate with

{{00:01:21}}
startup companies to jointly

{{00:01:22}}
CODEVELOP solutions for some

{{00:01:24}}
of the business challenges

{{00:01:25}}
that AstraZeneca face,

{{00:01:26}}
not just in Australia, but

{{00:01:28}}
across the globe as well.

{{00:01:29}}
So through the A Catalyst

{{00:01:30}}
network, what we also do is

{{00:01:32}}
once the solution is proven

{{00:01:34}}
in the particular market, we

{{00:01:35}}
scale it up and launch those

{{00:01:37}}
products and technologies and

{{00:01:39}}
solution across the globe.

{{00:01:40}}
So that way we are helping

{{00:01:42}}
to scale up the solution

{{00:01:43}}
of startup companies to

{{00:01:45}}
grow to the next phase

{{00:01:46}}
They're looking for.

{{00:01:47}}
Our business strategy always

{{00:01:49}}
start with understanding

{{00:01:50}}
the patient journey in each

{{00:01:52}}
therapeutic area that we

{{00:01:53}}
play in, you know, from a

{{00:01:54}}
disease awareness diagnostics,

{{00:01:57}}
treatment, and of course

{{00:01:58}}
the medication adherence

{{00:02:00}}
and disease management,

{{00:02:01}}
ongoing disease managements.

{{00:02:03}}
So we look at entire patient

{{00:02:04}}
journey to understand.

{{00:02:05}}
Where are the key pain points

{{00:02:07}}
for the patient and healthcare

{{00:02:08}}
provider and healthcare

{{00:02:09}}
system in the country.

{{00:02:11}}
And then work with external

{{00:02:12}}
partners to collaborate to

{{00:02:14}}
address those pain points

{{00:02:15}}
so the patient have a better

{{00:02:17}}
clinical outcome and also

{{00:02:18}}
better experience as they go

{{00:02:20}}
through the treatment process.

{{00:02:21}}
So we are working

{{00:02:21}}
with digital company.

{{00:02:23}}
Telehealth companies, AI,

{{00:02:26}}
in lung cancer diagnostics.

{{00:02:28}}
We also working with

{{00:02:29}}
the companies, in the

{{00:02:30}}
point of care testing.

{{00:02:32}}
So we work with the broad set

{{00:02:33}}
of healthcare stakeholders,

{{00:02:35}}
across the different

{{00:02:37}}
industries and the care

{{00:02:38}}
continuum to bring in new

{{00:02:40}}
solutions and products so that

{{00:02:42}}
that will enhance the patient

{{00:02:43}}
experience and clinical

{{00:02:44}}
outcome of the patients.

{{00:02:45}}
AstraZeneca collaborative

{{00:02:47}}
startup Ecosystem Australia,

{{00:02:48}}
I know in fact across the

{{00:02:49}}
globe in, in two ways.

{{00:02:51}}
One is how do we give

{{00:02:53}}
back to them our expertise

{{00:02:55}}
and experience that we

{{00:02:56}}
have within AstraZeneca.

{{00:02:57}}
So we have a global mentoring

{{00:02:59}}
program through partnership

{{00:03:00}}
with Australia and CSARO

{{00:03:02}}
and also the three leading

{{00:03:04}}
universities in Australia,

{{00:03:05}}
UNSW, the Queensland, and

{{00:03:08}}
also University of Western

{{00:03:09}}
Australia, where we own

{{00:03:11}}
offering our mentoring program

{{00:03:12}}
to those startup companies

{{00:03:14}}
and researchers to, to

{{00:03:16}}
accelerate their innovation

{{00:03:18}}
to bring product and services

{{00:03:20}}
to the patients quicker.

{{00:03:21}}
So one way is to sharing

{{00:03:23}}
our knowledge and expertise

{{00:03:24}}
with the wider healthcare

{{00:03:26}}
ecosystem and startups.

{{00:03:27}}
Second one, we collaborate,

{{00:03:29}}
actually jointly develop

{{00:03:30}}
solutions, where we have

{{00:03:32}}
an idea or startup company

{{00:03:33}}
has an idea that address

{{00:03:35}}
one of the pain point that

{{00:03:36}}
our business is facing.

{{00:03:37}}
How do we jointly create

{{00:03:39}}
validate and then test

{{00:03:42}}
that in the market?, and

{{00:03:43}}
then if it work, then scale

{{00:03:44}}
it up across the world.

{{00:03:45}}
So that's how, two different

{{00:03:47}}
ways that we collaborate with

{{00:03:48}}
the wider innovation ecosystem

{{00:03:50}}
and the startup companies.

{{00:03:51}}
The pandemic has really

{{00:03:52}}
accelerated the development

{{00:03:54}}
and adaptation of digital

{{00:03:55}}
technologies and the

{{00:03:56}}
digital health and digital

{{00:03:58}}
therapeutics and AI.

{{00:03:59}}
So what it is, is impacting

{{00:04:01}}
the entire value chain of

{{00:04:02}}
the pharmaceutical industry,

{{00:04:03}}
not just AstraZeneca alone.

{{00:04:05}}
So whether it's being drug

{{00:04:07}}
development, clinical trial,

{{00:04:08}}
10 years ago, it takes a

{{00:04:09}}
billion dollar to bring

{{00:04:10}}
a MAR product to market.

{{00:04:13}}
Now it has balance to almost

{{00:04:14}}
2 billion in last 10 years.

{{00:04:15}}
So how do we use the digital

{{00:04:18}}
tech technology and AI

{{00:04:19}}
to optimize and far track

{{00:04:21}}
drug development, drug

{{00:04:23}}
identifications, candidate

{{00:04:24}}
identifications, and also the

{{00:04:25}}
clinical trial so we can get

{{00:04:27}}
these products and services

{{00:04:28}}
to patients at affordable

{{00:04:30}}
pricing and also at fast rate.

{{00:04:33}}
The second one, from a

{{00:04:34}}
commercial perspective,

{{00:04:35}}
the remote patient care

{{00:04:37}}
has increased the access

{{00:04:39}}
to medication treatment

{{00:04:40}}
to broader patient pool,

{{00:04:42}}
at a quicker space and

{{00:04:44}}
also more efficient way.

{{00:04:45}}
So how do we then work with

{{00:04:46}}
the digital health companies,

{{00:04:48}}
healthcare ecosystems,

{{00:04:49}}
healthcare partners, to have

{{00:04:51}}
increase the ECU of access for

{{00:04:53}}
medication and treatment to

{{00:04:54}}
the different people,  respect

{{00:04:57}}
where they do their life?

{{00:04:58}}
So that way we had a positive

{{00:05:00}}
impact on the industry

{{00:05:02}}
broadly, and it's about how

{{00:05:03}}
do we take those opportunities

{{00:05:05}}
and really make a difference

{{00:05:06}}
in patient's life and improve

{{00:05:08}}
their clinical outcome and

{{00:05:09}}
their patient experience.

Expert Insight

Join us for an insightful interview with Kumaran Mani (Associate Director of Business Development, Digital Health and Healthcare Innovation Hub Lead - Australia & New Zealand) as he discusses the challenges facing healthcare startups in Australia. 

Discover how AstraZeneca's Catalyst network plays a crucial role in supporting these startups and helping them address obstacles in accessing expertise and commercializing their technologies.